BIOMAT Database Logo BIOMAT Database Logo

Prophylactic treatment for superficial bladder cancer following transurethral resection. 1987

Y Hirao, and E Okajima, and S Ohara, and S Ozono, and T Hiramatsu, and K Yoshida, and K Yamada, and H Aoyama, and M Hashimoto, and S Watanabe
Department of Urology, Nara Medical University, Kashihara, Japan.

A total of 130 primary cases with superficial bladder cancer were entered in the prospective randomized group study. The prophylactic treatments compared consisted in intravesical instillation of adriamycin (20 mg/-40 ml or 30 mg/30 ml), mitomycin C (20 mg/40 ml) or thio-TEPA (30 mg/30 ml), and noninstillation treatments with etretinate or tegafur; control patients were also studied. All agents were administered for 2 years. Recurrences were significantly suppressed in the instillation groups compared with control and non-instillation groups. Significant suppression of recurrence was observed in stage 1 or grade 2 disease treated with prophylactic instillation administered over the first 24 months of a 48-month observation period. These results may indicate the clinical usefulness of prophylactic instillation, but the long-term effect of intravesical instillation is still uncertain. A long-term follow-up study is therefore necessary.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell

Related Publications

Y Hirao, and E Okajima, and S Ohara, and S Ozono, and T Hiramatsu, and K Yoshida, and K Yamada, and H Aoyama, and M Hashimoto, and S Watanabe
[Superficial bladder cancer: Transurethral resection and instillation therapy].
April 2015, Der Urologe. Ausg. A,
Y Hirao, and E Okajima, and S Ohara, and S Ozono, and T Hiramatsu, and K Yoshida, and K Yamada, and H Aoyama, and M Hashimoto, and S Watanabe
Efficacy and safety of transurethral resection of bladder tumor for superficial bladder cancer.
January 2021, American journal of translational research,
Y Hirao, and E Okajima, and S Ohara, and S Ozono, and T Hiramatsu, and K Yoshida, and K Yamada, and H Aoyama, and M Hashimoto, and S Watanabe
[Short-term intravesical instillation of pirarubicin (THP) in prophylactic treatment after transurethral resection of superficial bladder tumor].
August 1998, Hinyokika kiyo. Acta urologica Japonica,
Y Hirao, and E Okajima, and S Ohara, and S Ozono, and T Hiramatsu, and K Yoshida, and K Yamada, and H Aoyama, and M Hashimoto, and S Watanabe
Results of transurethral resection plus adjuvant intravesical chemotherapy for superficial bladder cancer.
November 1998, International journal of urology : official journal of the Japanese Urological Association,
Y Hirao, and E Okajima, and S Ohara, and S Ozono, and T Hiramatsu, and K Yoshida, and K Yamada, and H Aoyama, and M Hashimoto, and S Watanabe
Clinical assessment of fluorescence cytoscopy during transurethral bladder resection in superficial bladder cancer.
January 1997, Urological research,
Y Hirao, and E Okajima, and S Ohara, and S Ozono, and T Hiramatsu, and K Yoshida, and K Yamada, and H Aoyama, and M Hashimoto, and S Watanabe
[A randomized study of prophylactic intravesical instillation of pirarubicin (THP) prior to transurethral resection of superficial bladder cancer].
July 2005, Hinyokika kiyo. Acta urologica Japonica,
Y Hirao, and E Okajima, and S Ohara, and S Ozono, and T Hiramatsu, and K Yoshida, and K Yamada, and H Aoyama, and M Hashimoto, and S Watanabe
[The value of differentiated transurethral resection in primary superficial bladder cancer].
March 1991, Der Urologe. Ausg. A,
Y Hirao, and E Okajima, and S Ohara, and S Ozono, and T Hiramatsu, and K Yoshida, and K Yamada, and H Aoyama, and M Hashimoto, and S Watanabe
[Prognostic factors of superficial bladder cancer recurring after initial transurethral resection].
April 2005, Hinyokika kiyo. Acta urologica Japonica,
Y Hirao, and E Okajima, and S Ohara, and S Ozono, and T Hiramatsu, and K Yoshida, and K Yamada, and H Aoyama, and M Hashimoto, and S Watanabe
Recurrence of superficial bladder tumours after transurethral resection.
January 1992, International urology and nephrology,
Y Hirao, and E Okajima, and S Ohara, and S Ozono, and T Hiramatsu, and K Yoshida, and K Yamada, and H Aoyama, and M Hashimoto, and S Watanabe
The role of the surgeon and transurethral resection in the treatment of superficial bladder cancer.
June 2006, TheScientificWorldJournal,
Copied contents to your clipboard!